Ph II data of perifosine + capecitabine in metastatic CRC to be presented at gastrointestinal cancer congress

Links shared publicly online about this topic.

1,057
total visits

Ph II data of perifosine + capecitabine in metastatic CRC to be presented at gastrointestinal cancer congress

Keryx Biopharmaceuticals, Inc. today announced that abstract O-0017, entitled "Subset Analysis of 5-FU Refractory Patients from a Randomized Ph II Study of Perifosine + Capecitabine (P-CAP) vs. Placebo + Capecitabine (CAP) in Patients with 2nd or 3rd Line Metastatic CRC" has been selected for oral presentation at the upcoming 12th World Congress on Gastrointestinal Cancer, to be held in Barcelona, Spain from June 30 - July 2, 2010.

View full resource at news-medical.net

Tags: Cancer, Cancer Medication, Colorectal Cancer Medication, Xeloda, 5-FU, Oncology